Nothing Special   »   [go: up one dir, main page]

BRPI0415759A - compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia - Google Patents

compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia

Info

Publication number
BRPI0415759A
BRPI0415759A BRPI0415759-1A BRPI0415759A BRPI0415759A BR PI0415759 A BRPI0415759 A BR PI0415759A BR PI0415759 A BRPI0415759 A BR PI0415759A BR PI0415759 A BRPI0415759 A BR PI0415759A
Authority
BR
Brazil
Prior art keywords
independently
optionally substituted
compounds
cor
heteroaryl
Prior art date
Application number
BRPI0415759-1A
Other languages
English (en)
Inventor
Shudong Wang
Gavin Wood
Kenneth W Duncan
Christopher Meades
Darren Gibson
Janice J Mclachlan
Alex Perry
David Blake
Daniella I Zheleva
Peter Fischer
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0324599A external-priority patent/GB0324599D0/en
Priority claimed from GB0330013A external-priority patent/GB0330013D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of BRPI0415759A publication Critical patent/BRPI0415759A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)

Abstract

"COMPOSTOS DE PIRIMIDIN-4-IL-3,4-TIONA E USO DOS MESMOS NA TERAPIA". A presente invenção refere-se aos compostos da fórmula: (I) ou sais farmaceuticamente aceitáveis dos mesmos, em que R¬ 1¬ e R¬ 5¬ São Cada um independentemente H, C(OR¬ j¬<39>) ou um grupo hidrocarbila opcionalmente substituído por um ou mais grupos R¬ 6¬; R¬ 2¬, R¬ 3¬ e R¬ 4¬ São cada um independentemente H, alquila ou alquenila, cada um dos quais pode ser opcionalmente substituído por um ou mais grupos R¬ 7¬; R¬ 6¬ e R¬ 7¬ São cada um independentemente halogênio, NO~ 2~, CN, (CH~ 2~)~ m~OR¬ a¬, O(CH~ 2~)~ n~OR¬ b¬ (CH~ 2~)~ p~NR¬ c¬R¬ d¬, CF~ 3~, COOR¬ e¬CONR¬ f¬R¬ g¬, COR¬ h¬, SO~ 3~H, SO~ 2~R¬ i¬, SO~ 2~NR¬ j¬R¬ k¬, (CH~ 2~)~ q~NR¬ a¬<39>COR¬ g¬<39>, R¬ f¬, (CH~ 2~)~ r~NR¬ b¬<39>SO~ 2~R¬ h¬<39>, SO~ 2~NR¬ d¬<39>R¬ i¬<39>, SO~ 2~NR¬ e¬ <39>(CH~ 2~)~ s~OR¬ c¬<39>, heterociclila ou heteroarila, em que o dito heterociclila e heteroarila podem ser opcionalmente substituídos por um ou mais substituintes selecionados de aralquila, sulfonila, R¬ m¬ e COR¬ n¬; R¬ g¬<39>, R¬ h¬<39>, R¬ i¬<39> e R¬ j¬<39> são cada um independentemente selecionados de alquila, arila, aralquila e heteroarila, cada um dos quais pode ser opcionalmente substituído por um ou mais substituintes selecionados de halogênio, OH, NO~ 2~, NH~ 2~ CF~ 3~ e COOH; m, p, q e r são cada um independentemente 0, 1, 2 ou 3; n e s são cada um independentemente 1, 2 ou 3; e R¬ a-n¬ e R¬ a<39>-f¬ são cada um independentemente H ou alquila. Aspectos adicionais da invenção refere-sem a composições farmacêuticas que compreendem tais compostos e o seu uso na preparação de um medicamento para o tratamento de um ou mais dos seguintes: um distúrbio proliferativo, um distúrbio viral, um distúrbio do SNC, um derrame, alopecia e diabete.
BRPI0415759-1A 2003-10-21 2004-10-21 compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia BRPI0415759A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0324599A GB0324599D0 (en) 2003-10-21 2003-10-21 Compound
GB0330013A GB0330013D0 (en) 2003-12-24 2003-12-24 Compound
PCT/GB2004/004465 WO2005042525A1 (en) 2003-10-21 2004-10-21 Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy

Publications (1)

Publication Number Publication Date
BRPI0415759A true BRPI0415759A (pt) 2006-12-19

Family

ID=34553788

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415759-1A BRPI0415759A (pt) 2003-10-21 2004-10-21 compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia

Country Status (8)

Country Link
US (1) US7902361B2 (pt)
EP (1) EP1678171B1 (pt)
JP (1) JP5164380B2 (pt)
AU (1) AU2004285745A1 (pt)
BR (1) BRPI0415759A (pt)
CA (1) CA2542880A1 (pt)
IL (1) IL174994A0 (pt)
WO (1) WO2005042525A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
GB0520955D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
WO2007054725A2 (en) * 2005-11-11 2007-05-18 Cyclacel Limited Combination of a cdk-inhibitor and a hdac-inhibitor
CA2628179A1 (en) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2379543A2 (en) 2008-12-18 2011-10-26 F. Hoffmann-La Roche AG Thiazolyl-benzimidazoles
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
CA2994023A1 (en) * 2015-08-04 2017-02-02 University Of South Australia N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP4205165B2 (ja) 1996-05-08 2009-01-07 サイクラセル リミテッド Ｃｄｋ４活性の阻害のための方法と手段
US6221873B1 (en) 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
ATE349443T1 (de) * 2001-09-28 2007-01-15 Cyclacel Ltd N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen
CA2491895C (en) * 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use

Also Published As

Publication number Publication date
IL174994A0 (en) 2006-08-20
EP1678171B1 (en) 2016-09-14
US20070021452A1 (en) 2007-01-25
US7902361B2 (en) 2011-03-08
EP1678171A1 (en) 2006-07-12
AU2004285745A1 (en) 2005-05-12
JP5164380B2 (ja) 2013-03-21
CA2542880A1 (en) 2005-05-12
WO2005042525A1 (en) 2005-05-12
JP2007509117A (ja) 2007-04-12

Similar Documents

Publication Publication Date Title
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BRPI0412351A (pt) derivados e piridilamino-pirimidina como inibidores de proteìna quinase
BRPI0516972A (pt) composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
AR055916A1 (es) Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0407699A (pt) Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam
BRPI0015203B8 (pt) derivado de quinazolina, composição farmacêutica, e, uso de um composto
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BRPI0418102A (pt) derivados de quinolina
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
BRPI0509795A (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso do composto ou sal farmacologicamente aceitável do mesmo, e, método para promover osteogênese, supressão de ressorção óssea e/ou melhoramento da densidade óssea
UY27333A1 (es) Nucleótidos 4` sustituidos
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BRPI0519287A2 (pt) derivados de amida
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
BRPI0511722A (pt) 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina
BR0102607A (pt) Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos
BRPI0515860A (pt) derivados de tetralin e indano, e uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.